頭頚部癌に対するNK-801(Cisplatin)の効果について

概要

論文の詳細を見る
Sixteen patients with head and neck cancer were treated with cis-diamminedichloroplatinum (Cisplatin). We used two kinds of regimen: low dose regimen (10mg/day iv or ia, day 1-5, q 3wk) and high dose regimen (80mg/day iv or ia, q 3wk). Eight patients were treated before radiotherapy or surgery for stage III or IV disease and the remaining eight were treated for recurrent or metastatic disease.The tumor was squamous cell carcinoma in 14, adenoid cystic carcinoma in one and adenocarcinoma in one case.The overall response rate was 33% with two complete response (14+, 6+) and 3 partial response (≥50% regression). In the high dose regimen we observed complete response in 2 and partial response in 2 cases, meanwhile in the low dose regimen we merely observed partial response in one case. There was no difference of therapeutic effect due to the route of administration.Toxicity was minimal: no patients had creatinine>2mg/dl: leucopenia (<3000/mm3) in one patient: nausea and vomiting in 69%; and minimal hearing loss in 2 patients.The most impressive point of this agent is that responses are complete in some cases with long remission durations.We concluded that Cisplatin was an effective new agent for squamous cell carcinoma of the head and neck. Further study should be performed for the purpose of developing new combination chemotherapy which includes this agent.
耳鼻咽喉科臨床学会の論文